Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Alan L. Shields, PhD
Vice President
Adelphi Values USA
Boston, MA
Vice President
Adelphi Values USA
Boston, MA
Authored Items
Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges
Alan L. Shields, PhD
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Yanni Hao, PhD
,
Meaghan Krohe, PhD
,
Andrew Yaworsky
,
Iyar Mazar, MA
,
Catherine Foley, MPH, MA
,
Faisal Mehmed, MD
,
Denise Globe, PhD
June 2016 Vol 9, No 4
in
Regulatory
Last modified: June 24, 2016
